63
Views
7
CrossRef citations to date
0
Altmetric
Review

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

, , , , , , , , , , & show all
Pages 547-558 | Published online: 11 Jul 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Takashi Kadowaki, Satsuki Muto, Yoshiumi Ouchi, Ryutaro Shimazaki & Yutaka Seino. (2017) Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert Opinion on Pharmacotherapy 18:18, pages 1903-1919.
Read now
Takashi Kadowaki, Fuyuhiko Marubayashi, Shoko Yokota, Makoto Katoh & Hiroaki Iijima. (2015) Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies. Expert Opinion on Pharmacotherapy 16:7, pages 971-981.
Read now

Articles from other publishers (5)

Takashi Kadowaki, Kazuyo Sasaki, Manabu Ishii, Miyuki Matsukawa & Yoshiteru Ushirogawa. (2018) Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies. Diabetes Therapy 9:2, pages 623-636.
Crossref
Chun-Jun Li, Bei Sun, Qian-Hua Fang, Min Ding, Yun-Zhi Xing, Li-Ming Chen & De-Min Yu. (2017) Saxagliptin Induces β-Cell Proliferation through Increasing Stromal Cell-Derived Factor-1α In Vivo and In Vitro. Frontiers in Endocrinology 8.
Crossref
Ira Gantz, Taro Okamoto, Yuka Ito, Kotoba Okuyama, Edward A. O'Neill, Keith D. Kaufman, Samuel S. Engel & Eseng Lai. (2017) A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism 19:11, pages 1602-1609.
Crossref
Ira Gantz, Taro Okamoto, Yuka Ito, Asako Sato, Kotoba Okuyama, Edward A. O’Neill, Samuel S. Engel & Eseng Lai. (2017) A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control. Diabetes Therapy 8:4, pages 793-810.
Crossref
Hiroyuki Konya. (2015) Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus. World Journal of Experimental Medicine 5:2, pages 110.
Crossref